Corporate Overview

Our focus on improving patient outcomes today while driving the development of tomorrow’s next-generation medical technology is what brings our mission to life. From pioneering beginnings to a promising pipeline, at Biosensors our success is due to our focus on research and development, clinical excellence and our talented team.

Through our high quality medical devices, we impact the lives we touch, and we are committed to continue investing in and developing pioneering medical technology, pharmacological research, and engineering new medical devices that will further benefit our patients. This will create the greatest possible patient outcomes, and provide value to our stakeholders including physicians, shareholders and employees.

Since 1990, we have been developing and marketing critical care catheter systems and related devices used during heart surgery and intensive care treatment. Always seeking to be at the forefront of product innovation, we entered the interventional cardiology market in 2000 with our proprietary coronary stent and accompanying stent delivery system. In the same year, we further expanded our product line to include angioplasty balloons and catheters.

In just two years, Biosensors has received CE Mark approvals for the first version of its BioMatrix™ drug-eluting stent (January 2008), its smaller-diameter (2.25 mm) version (March 2009) and finally the BioMatrix Flex™ (January 2010). The BioMatrix Flex™ stent has been approved for a comprehensive range of indications, including STEMI, Acute Coronary Syndromes and Diabetes Mellitus.

Our abluminal drug-eluting stent system is a unique combination of our proprietary anti-restenotic BA9™ (Biolimus A9™) drug and biodegradable PLA polymer. Together with an advanced and highly flexible stent platform designed for enhanced deliverability, it offers a true next-generation solution for patients everywhere.